Pfizer (PFE) announced results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor Tukysa as part of an investigational ...

Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. Inebilizumab gains ...

For the first time, researchers have determined how a human olfactory receptor captures an airborne scent molecule, the pivotal chemical event that triggers our sense of smell. Whether it evokes roses ...